Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.69 |
| ▸ | EBP | Q15125 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.54 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.53 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.50 |
| ▸ | GCGR | P47871 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trioxifene SCHEMBL29464170 | 1.00 | ESR1 (0.69) | ESR1ESR2EBPSIGMAR1LTA4H | |
| SCHEMBL4650720 | 0.99 | ESR1 (0.70) | ESR1ESR2EBPSIGMAR1LTA4H | |
| Trioxifene SCHEMBL7753024 | 0.99 | ESR1 (0.68) | ESR1ESR2EBPSIGMAR1LTA4H | |
| SCHEMBL4651968 | 0.99 | ESR1 (0.70) | ESR1ESR2EBPSIGMAR1LTA4H | |
| SCHEMBL7532746 | 0.95 | ESR1 (0.65) | ESR1ESR2EBPSIGMAR1LTA4H | |
| SCHEMBL6592276 | 0.94 | ESR1 (0.76) | ESR1ESR2EBPSIGMAR1LTA4H | |
| SCHEMBL11180048 | 0.93 | ESR1 (0.69) | ESR1ESR2EBPSIGMAR1LTA4H | |
| SCHEMBL11176566 | 0.93 | ESR1 (0.69) | ESR1ESR2EBPSIGMAR1LTA4H | |
| SCHEMBL4660156 | 0.92 | ESR1 (0.79) | ESR1ESR2EBPSIGMAR1LTA4H | |
| SCHEMBL4651846 | 0.91 | ESR1 (0.81) | ESR1ESR2EBPSIGMAR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-05 | — | — | US | claimed |
| US-20040127440-A1 | Methods and compositions for control of bone formation via modulation of neuropeptide Y activity | BAYLOR COLLEGE OF MEDICINE | 2004-07-01 | — | — | US | claimed |
| US-20040053864-A1 | Methods and compositions for control of bone formation via modulation of neuropeptide y activity | BAYLOR COLLEGE OF MEDICINE | 2004-03-18 | — | — | US | claimed |
| US-5514675-A | ADMINISTERING TO TREAT ASTHMA, RHINITIS, AND PAIN; ANTISHOCK AND HYPOTENSIVE AGENTS | ELI LILLY AND COMPANY (US) | 1996-05-07 | — | — | US | claimed |
| EP-2002827-A2 | Methods and compositions for control of bone formation via modulation of sympathetic tone | THE BAYLOR COLLEGE OF MEDICINE (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1093803-B1 | Cosmetic composition comprising an antagonist of the neuropeptide Y receptor | SANOFI AVENTIS (FR) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077333-A2 | USE OF A NEUROPEPTIDE Y ANTAGONIST FOR DAMAGED OR SENSITIVE LIPS | L'OREAL (FR) | 2007-07-12 | — | — | WO | disclosed |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-05 | — | — | US | disclosed |
| US-20060165683-A1 | Methods and compositions for control of bone formation via modulation of sympathetic tone | BAYLOR COLLEGE OF MEDICINE | 2006-07-27 | — | — | US | disclosed |
| EP-1542719-A4 | METHODS AND COMPOSITIONS FOR CONTROL OF BONE FORMATION VIA MODULATION OF SYMPATHETIC TONE | BAYLOR COLLEGE MEDICINE (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1330251-A4 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-SENSITIVE DISEASE | INTARCIA THERAPEUTICS INC (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050232862-A1 | Combination therapy for the treatment of estrogen-sensitive drugs | INTARCIA THERAPEUTICS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-4775660-A | Treatment of breast cancer by combination therapy | LABRIE FERNAND (CA) | 1988-10-04 | — | — | US | disclosed |
| US-4775661-A | Combination therapy for treatment of female breast cancer | LABRIE FERNAND (CA) | 1988-10-04 | — | — | US | disclosed |
| US-4760053-A | Combination therapy for selected sex steroid dependent cancers | LABRIE FERNAND (CA) | 1988-07-26 | — | — | US | disclosed |
| EP-0195015-A1 | PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY OF HORMONE DEPENDENT CANCERS. | LABRIE FERNAND (CA) | 1986-09-24 | — | — | EP | disclosed |
| WO-1986001105-A1 | PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY OF HORMONE DEPENDENT CANCERS | LABRIE FERNAND (CA) | 1986-02-27 | — | — | WO | disclosed |
| US-4400543-A | ANTIFERTILITY AGENTS | ELI LILLY AND COMPANY (US) | 1983-08-23 | — | — | US | disclosed |
| US-4323707-A | USEFUL FOR AMIMALS, AROYL-PHENYL-NAPHTHALENES OR DIHYDRONAPHTHALENES | ELI LILLY AND COMPANY (US) | 1982-04-06 | — | — | US | disclosed |
| US-4230862-A | 3-PHENYL-4-AROYL-1,2-DIHYDRONAPHTHALENES AND 1-ARYOYL-2-PHENYLNAPHTHALENES | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050232862-A1 | Combination therapy for the treatment of estrogen-sensitive drugs | ESR2, ESR1, ESRRB | ESR1 2/4885ESR2 1/4885EBP 144/4885 |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | PSEN2, APP, PSEN1 | ESR1 208/4885ESR2 46/4885EBP 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.